🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. MIDAZOLAM , PROPOFOL , ROCURONIUM BROMIDE , Cipepofol Injectable Emulsion, FENTANYL , SEVOFLURANE , PROPOFOL

    Lacuna Pharma Pty Ltd

    General anaesthesia

    phase 3 small molecule active

    1 trial

  2. MIDAZOLAM, DEXMEDETOMIDINE EVER PHARMA 100 microgrammes/mL, solution à diluer pour perfusion

    Pari Pharma GmbH

    Very preterm neonate (gestational age at birth < 32 WG) with corrected gestational age <45 WG) with indication for sedation in the context of invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  3. MINJUVI 200 mg powder for concentrate for solution for infusion

    Incyte

    Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia

    phase 3 small molecule active

    1 trial

  4. MK-0616, Placebo to MK-0616

    Merck Sharp and Dohme

    ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients

    phase 3 small molecule active

    1 trial

  5. MK-0616, Placebo to MK-0616 - Tablet

    Merck Sharp and Dohme

    ASCVD - Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  6. MK-2870, CAPECITABINE , CYCLOPHOSPHAMIDE , PACLITAXEL , DEXAMETHASONE , DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, EPIRUBICIN , CARBOPLATIN

    Merck Sharp and Dohme

    Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer

    phase 3 small molecule active

    1 trial

  7. MK-2870, GEMCITABINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , -, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    Merck Sharp and Dohme

    Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10

    phase 3 small molecule active

    1 trial

  8. MK-2870, PARACETAMOL , TOPOTECAN , -, TISOTUMAB VEDOTIN, IRINOTECAN , PEMETREXED , -, -, GEMCITABINE , MK-2870, VINORELBINE

    Merck Sharp and Dohme

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    phase 3 small molecule active

    1 trial

  9. MK-3543, HYDROXYCARBAMIDE , Placebo for hydroxycarbamide, MK-3543, MK-3543, MK-3543, Placebo for Bomedemstat

    Merck Sharp and Dohme

    Essential thrombocythemia

    phase 3 small molecule active

    1 trial

  10. MK-3543, MK-3543, MK-3543, MK-3543

    Merck Sharp and Dohme

    Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

    phase 3 small molecule active

    1 trial

  11. MK-6194, Placebo for MK-6194

    Merck Sharp and Dohme

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  12. MOVIPREP

    Takeda

    Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

    phase 3 small molecule completed

    1 trial

  13. MOXIFLOXACIN, CLOFAZIMINE, PRETOMANID, LINEZOLID, BEDAQUILINE

    Pari Pharma GmbH

    Patients diagnosed at the study sites with rifampicinresistant tuberculosis during the recruitment period will be evaluated for study inclusion.

    phase 3 small molecule active

    1 trial

  14. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 small molecule completed

    2 trials

  15. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  16. MPs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hematological Diseases

    phase 3 mab active

    1 trial

  17. MRI

    United Therapeutics Europe Ltd

    Prostate Neoplasm

    phase 3 other completed

    1 trial

  18. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  19. MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    phase 3 small molecule active

    1 trial

  20. MYCOPHENOLATE MOFETIL, PREDNISOLONE , MYCOPHENOLATE MOFETIL, AZATHIOPRINE, Gazyvaro 1,000 mg concentrate for solution for infusion., AZATHIOPRINE

    Pari Pharma GmbH

    lupus nephritis

    phase 3 small molecule active

    1 trial

  21. MYCOPHENOLIC ACID, -, MYCOPHENOLATE MOFETIL, VAY736, TENOFOVIR ALAFENAMIDE , ENTECAVIR , TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  22. MYCOPHENOLIC ACID, TENOFOVIR ALAFENAMIDE , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe , Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, VAY736, ENTECAVIR , -, TENOFOVIR DISOPROXIL , VAY736, MYCOPHENOLATE MOFETIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  23. MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule completed

    2 trials

  24. MYOBLOC Low Dose

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources